Report to the Board

Board -2021 -Mtg -4-Doc 01d -Annex H

Annex H: Summary of approved and p roposed baselines /targets for Gavi 5.0 indicators
ID Indicator name Baseline 2025 target
MISSION INDICATORS
M.1 Under -five mortality 58 per 1,000 -10% reduction
M.2 Future deaths averted ? 7-8m
M.3 Future DALYs averted ? 320 -380m
M.4 Reduction in zero -dose 9.7m -25%
M.5 Unique children immunised ? 300m
M.6 Economic benefits unlocked ? US$80 -100b
STRATEGY GOAL 1: INTRODUCE AND SCALE UP VACCINES
S1. 1 Breadth of protection 56% +16pp
S1.2 SDG3.b.1
DTP3 81% +4pp
MCV2 58% +13pp
PCV3 53% 23pp
HPV2 8% +17pp
S1.3 Rate of scale up of new vaccines
PCV3
n/a 90% Rotac
MCV2
YF
S1.4 Vaccine introductions ? 82
S1.5 Country prioritisation ? ?1
S1.6 Preventative campaign reach (measles) ? 50%
S1.7 Timely outbreak detection and response 25% 50% increase
STRATEGY GOAL 2: STRENGTHEN HEALTH SYSTEMS AND EQUITY IN IMMUNISATION 2
S2.1 Geographic equity DTP3 coverage 67% +7pp
S2.2 DTP drop -out 7% -1pp
S2.3 MCV1 coverage 80% +4pp
S2.4 Number of immunisation sessions n/a n/a
S2.5 Stock availability at facility level n/a n/a
S2.6 EPI management capacity n/a n/a
S2.7 Plans to overcome demand barriers n/a n/a
S2.8 Gender -related barriers n/a n/a
STRATEGY GOAL 3: IMPROVE SUSTAINABILITY OF IMMUNISATION PROGRAMMES
S3.1 Co -financing fulfillment 100% 100%
S3.2 Preventing backsliding in Gavi -transitioned countries ?3 No decline 4
S3.3 (If applicable) Vaccine introductions ( PCV, Rota, HPV)
catalyzed in Gavi -transitioned countries TBD TBD
STRATEGY GOAL 4: ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTS
S4.1 Healthy market dynamics ? 10
S4.2 Incentivise innovations ? 8
S4.3 Scale -up innovations ? 9
NB: Baselines and targets for greyed out indicators were approved by the Gavi Board in June 2021 .
1 Target not set for this indicator due to ongoing uncertainties regarding future implementation of the Vaccine Investment Stra tegy. 2 The Gavi Board approved (December 2020) to the proposal that no targets be set for indicators S2.4 to S2.8. They will be m onitored for directionality as the Alliance establishes and strengthens systems to consistently collect quality data. 3 Baseline for this indicator is 2021. The baseline will be set in 2022, once 2021 immunisation coverage estimates are published. 4 No num eric value for 2025 target , which is framed as the proportion of Gavi -transitioned countries at least sustaining performance.

1



Board -2021 -Mtg -4-Doc 01d
Report to the Board
30 November - 2 December 2021

Section A: Introduction
Ten recommendations are being presented to the Board under the Consent
Agenda for consideration. Detailed information on the item s can be found in the
relevant Committee paper in a dedicated folder on BoardEffect at :
https://gavi.boardeffect.co.uk/workrooms/6459/resources/147743
Section B: Actions requested of the Board
The Gavi Alliance Board is requested to consider the following recommendation s
from the Gavi Alliance Governance Committee , Programme and Policy Committee
and Evaluation Advisory Committee .
Decision One ? Board Vice Chair Appointment

The Gavi Alliance Governance Committee recommend s to the Gavi Alliance
Board that it :

a) Reappoint Sarah Goulding as Board member representing Australia on the
donor constituency anchored by the United States, effective 1 January 2022
and until 31 December 2023; and

b) Reappoint Sarah Goulding as Vice Chair of the Board with individual signatory
authority, effective 1 January 2022 and until 31 December 2023 .
Decision Two ? Board and Committee Member Appointments
The Gavi Alliance Governance Committee recommend s to the Gavi Allian ce
Board:
a) That it appoint the following Board Members:
? Bernhard Braune as Board Member representing Germany on the donor
constituency anchored by Germany in the seat currently held by Joan
Valadou of France, effective 1 January 2022 and until 31 December 2 022.
? Rafael Vilasanjuan as Board Member representing the civil society
organisations constituency in the seat currently held by Maty Dia, effective
1 January 2021 and until 31 December 2023.
SUBJECT: CONSENT AGENDA ? UPDATED AS AT 30 NOV 2021
Agenda item: 01 d
Category: For Decision

Board -2021-Mtg -4-Doc 00a




G avi Alliance Board Meeting
30 November - 2 December 202 1 - Virtual Meeting

Tuesday 30 November : 14.30 -17.45 Genev a Time
Wednesday 1 December : 13.30 -18.30 Geneva Time
Thursday 2 December : 13.30 -18. 30 Geneva Time
Quorum: 14

Document list

No. Docu me nt
00a Document list
00b Agenda
01a Declarations of interest
01b Minutes
01c No Objection Consent Decisions
01d Consent Agenda
01 e Workplan
02 Committee Chair and IFFIm Board reports ? To follow
03 Financial Upda te, including forecast
04 Report from Audit & Investigations
05 CEO ?s Report ? To follow
06 Strategy, Programmes and Partnerships: Progress, Risks and Challenges
07a COVAX : Ke y Strategic Issues
07b COVAX: Resource Mobilisation Update
08 Malaria Vac cine Programme Investment Case
09 Risk Management Update
10 Strategic Partnership with India
11 Private Sector Engagement Strategy
12 Disease Surveillance and Diagnostics to Support Targeted Vaccination in Gavi 5.0
13 Review of decisions ? No paper
14 Closing remarks (including tri bute to departing Board M embers) ? No paper
No. Ad ditional Doc uments f or Informa tion (on Boa rdEffect )
A Board and Committee minutes (For i nformation only)
B CEPI 2020 Annual Progress Report

Board -2021-Mtg -04-Doc 00b








G avi Alliance Board Meeting
30 November ? 2 December 2021
Virtual Meeting



Tuesday 30 November : 14.30 -17.45 Geneva Time
Wednesday 1 December : 13.30 -18.30 Geneva Time
Thursday 2 December : 13.30 -18. 30 Geneva Time
Quorum: 14



A gend a








Nex t Board Me eting s: 6-7 April 2022 (Board Retreat )
22 -23 June 2022
7-8 D ecember 20 22

---
Brenda Killen , Director, Governance and Secretary t o the Board, +41 22 9 09 6680 , bkillen @gavi.org
Joanne Goetz , Head, Governa nce, + 41 22 9 09 6 544, jgoetz@gavi.org
Please note that the Board mee ting will be recorded. This recording will be used as an aid to minute t he meeting .
A transcr iptio n of the full proceedings will not normally be made . Shou ld a tr ansc riptio n be mad e it wil l be used
only as an aid to minute the meeting .




Boar d-2021-Mtg-04-Doc 00b 2

Board M eeting - D AY ONE ? Tuesday 30 November 2021

Item Sub ject Action Schedule

Closed Session: For Board Members and Alternate Board
Members only
14.30 -15. 15
1 Chair?s report
? Declarat ions of in terest
? Minutes
? No Objection Cons ent Decisions
? Consent Agenda 1,2
? Wor kpla n
Jos ? Ma nuel Barroso , Board Chair
DECISION 15. 15 -15. 30
2 Comm ittee Chair and IFFIm Board reports
? Go vernance Committe e ? Sarah Gou lding
? Audit and Finance Committee ? David Si dwell
? Inve stmen t Committee ? Afsaneh Beschloss
? Progr amme and Policy Committee ? Helen Re es
? Evalua tion Advisory Comm ittee ? James Hargreaves
? IFFI m Comp any ? Kenneth G Lay
15. 30 -16. 30
3 Financ ial Update, including forecast
Dav id Sidwe ll, Chair, Audit and F inance Com mittee
Assie tou Diou f, Managing Director , Finance & Oper ations
DECI SION 16. 30 -17.15
4 Re port from Audit & In vestigations
Simon Lamb, Managing Director, Audit & Investigations
17. 15 -17. 45
1 Any Board m ember can ask tha t an y item be removed from the consent agenda for f urth er dis cuss ion. S hould
there be any such reques t, the relevant discussion will take place on Day Three of the Board meet ing,
immedia tely precedin g t he R evie w o f Decisi ons. 2 Will include Board Vice Chair appointment, Committee Chair Appointments , Board and Committee
appointments, IRC appoin tments, Evaluat ion Policy, Corporate Treasur y Policies , Program me Funding Policy ,
AFC Ch art er, COVAX Shareholders Council To Rs, Meas urement Framework, CSCE Approach

Bo ard -2021-Mt g-4-Doc 0 1a




Gavi Alliance Board Meeting
30 November ? 2 December 202 1
Virtual Meeting
Quorum: 1 4
Declarations of Interest

Declarations
Section 5.5 of the Conflicts of Interest Policy for Governance Bodies states ?Members
involved in decisio n-makin g proce sses on b eha lf of Gavi must take appropriate action to
ensure disclosure of Interests and Conflicts of Inter est, and take the necessary action in
respect thereof.?
Section 6.2 of the Conflicts of Interest Policy for Governance Bodies further states , ?T he duty
to d isc lose [in 6.1 above] is a continuing obligation. This means that Members are obliged to
disclose any Interests and/or Conflict of Interest, whenever the Member comes to know the
relevant matter.?
The following declarations were made b y me mbe rs of the Bo ard on their most recent annual
statements .
Board members:
Member Org anisational Interest s

Financial/Personal/Advisor Int /
Others














Jos? Manuel Barroso , Chair




























Non e














Goldman Sachs I nter national
(Chairman and Non -Executive
Director -Advisor ); Princeton
University - Princeton School of
Public Policy, LISD, (Non
Residen t Fellow ); Catholic
Unive rsity o f Portugal (Visiting
Professor ); Centre fo r Euro pean
Stu die s (Director) ; Graduate
Insti tute of International and
Development Studies -Geneva,
(Visiting Professor ); The
EUROPEAUM (Board Member );
WPL -Women Political Leaders
(Advisory Board Member ); Je an
Monn et Foundation for Europe
(Honorary Committee Member );
Eur ope an C entre for C ulture,
(Honorary Co -President );
Portuguese Diaspora Council
(Chairman General Assembly );
Bilderberg Meetings (Steering
Committee Member ); Concordia
(Leade rship Member Council );
Wo rld Lea dership Alliance - Club
de Madrid (Memb er); Teatro Real
Ma drid (Internation al Council
member ); Royal Institute of
International Affairs (Chattam

Board -2021 -Mtg -02 1
Minutes




Gavi Alliance Board Meeting
23-24 June 2021
Virtual meeting


1. Chair?s Report

1.1 Finding a quorum of members present, the meeting commenced at 14. 00 Geneva
time on 23 June 2021 . Prof Jos? Manuel Barroso , Board Chair, chaired the
meeting.

1.2 The Chair welcomed one new Board member , Jeremy Konyndyk (United
States/Australia/Japan/ Korea (Rep. of)) . He also welcomed Zulfiqar Bhutta ,
interim Chair of the Evaluation Advisory Committee ; Ken neth Lay , Chair of the
International Finance Facility for Immunisation (IFFIm) ; and other directors of the
IFFIm Board , as we ll as Minister Harsh Vardhan (India) who was joining a Board
meeting for the first time.

1.3 Prof Bar roso reported that i n closed session earlier in the day, Board members
ha d approved a recommendation by the Governance Committee to reappoint Dr
Seth Berkley as Chief Executive Officer (CEO ) for a further exceptional one -year
term effective 3 August 2022.

1.4 He noted the exceptional ly busy agenda of the Board and its Committees and
referred to the Organisational Review update that had been shared with the Board
in advance of the Board meeting. He noted that a dedicated informal session for
Board members would be organised in the near future to further discuss the deta ils
of the review.

1.5 The Chair presented a short summary of the recent All Chairs Group (ACG)
meeting on 18 June 2021 , during which the Group had discussed the importance
of retaining Gavi?s focus on Gavi 5.0 commitments in addition to the Covax work .
He also reported that the Market Sensitive Decisions Committee (MSDC) had met
three times since the Board last convened.

1.6 Prof Barroso provided some personal reflections to the Board with regard to the
imperative of delivering on Gavi 5.0 and COVAX with the same level of ambition.
He noted that equity has not yet been achieved in COVID -19 vaccine coverage,
particularly in Africa. He made an urgent appeal in favour of Africa, particularly to
vaccine suppliers.

1.7 Standing declarations of interest were tabled to the Board (Doc 01a in the Board
pack).

1.8 The Board noted its minutes from 29 -30 September 2020 (Doc 01b) and 15 -17
December 2020 (Doc 01c) which were approved by no objection on 21 May 2021 ,

1



Board -2021 -Mtg -4-Doc 01c
Report to the Board
30 November - 2 December 2021



Since the June 2021 Board meeting, three decision s ha ve been circulated to the
Board electronically for approval by no -objection consent in line with Section 11 of
the Board and Board Committee Operating Procedures .

1) On 19 July 2021 , Board members were invited to consider approval of the
appointment of an Alternate Board Membe r.

No objections were received prior to the end of 29 July 2021 and the following
decision was therefore entered into the record:

In accordance with Section 11.3 of the Board and Board Committee Operating
Procedures, on a no -objection basis, the Gavi Alliance Board:

Appointed Gilbert Mokoki of Republic of Congo as Alternate Board Member
representing the implementing country constituency in the seat currently held
by Jacqueline Lydia Mikolo of Congo, effective immediately and until
31 December 2021 .

2) On 8 September 2021 , Board members were invited to consider approval of
the appointment of Board Members a nd a Governance Committee
Member.

No objections were received prior to the end of 21 September 2021 and the
following decision was therefore entered into the record:

In accordance with Section 11.3 of the Board and Board Committee Operating
Procedures, on a no -objection basis, the Gavi Alliance Board:

a) Appointed Faisal Sultan of Pakistan as Board Member representing the
implementing country constituency in the seat fo rmerly held by Assad
Hafeez of Pakistan, effective immediately and until 31 December 2023.

b) Appointed Mansukh Mandaviya of India as Board Member representing
the implementing country constituency in the seat currently held by Harsh
Vardhan of India, effective immediately and until 31 December 2023.

SUBJECT: NO -OBJECTION CONSENT DECISIONS
Agenda item: 01 c
Category: For Information

1


Re port to the Board

Board -2021 -Mtg -4-Doc 01d -Annex A
Annex A : IR C members proposed for reappointment for a second term, until
March 2025

Name Nationality
1 Saidou Path? Barry Guinea
2 Blaise Bikandou Congo
3 Francois Boilloit France
4 Dah Cheikh Mauritania
5 Ren ? Dubbeldam Holland
6 Peter Fonkwo Cameroun
7 Mathieu Noirhomme Belgium
8 Cornelius Oepen Germany
9 Elisabeth Paul Belgium
10 Jim Setzer USA

1


Re port to the Board

Board -2021 -Mtg -4-Doc 01d -Annex B
Annex B: IRC members proposed for e xceptional extension until March 202 4

Name Nationality
1 Aleksandra Caric Croatia
2 Osman David Mansoor New Zealand
3 Benjamin Nkowane Zambia

December 2021
AUDIT AND FINANCE COMMITTEE CHARTER
1. P U RP O S E
The Audit and Finance Committee (?Committee? or ? the AFC?) is established by the
Board (?Board?) of the Gavi Alliance (?Gavi?) to support the Board in fulfilling its
oversight responsibilities in a timely manner in respect of Gavi?s financial
management, risk and control framework, including internal and external audit, and
adherence to appropriate standards of good practices and ethics.
The Committee will review, monitor and make recommendations to the Board on the
areas within its scope of responsibilities a nd on any other matters which the Board
may request.
Words and expressions used in this Charter shall, unless the context requires
otherwise, have the meaning attributed to them in the Gavi Board and Board
Committee Operating Procedures (?Operating Procedures?) .
2. M E M B E RS H I P
The membership , resources, responsibilities and authorities of the Committee to
perform its role effectively are stipulated in this Charter, which may be amended by
the Board as and when required or deemed necessary and are specifically governed
by Article 1 8 of the Statutes and Section 18 of the Operating Procedures.
A. Composition and size
The composition of the AFC shall allow it to function efficiently and effectively in
fulfilling its functions and responsibilities . The composition of the AFC is intended to
comprise individuals suitabl y competent in the affairs and issues falling within the
Charter so as to be able to provide the Board and the Secretariat with sound advice on
matters set out in this Charter.
The AFC shall comprise not less than three members . A majority of the AFC members
shall comprise Board M embers and Alternate Board M emb ers. This provision shall
exclude Committee members representing i mplementing country governments .
Committee D elegates, as defined in S ection 18.9 of the Operating Procedures, shall be
eligible for membership on the AFC and shall resign or be removed in accordance with
S ection 5 of the Operating Procedures .

Doc 01d - Annex C

December 2021
COVAX FACILITY SHAREHOLDERS COUNCIL
TERMS OF REFERENCE
1. Purpose
The COVAX Facility Shareholders Council (?the Council?) is established by the Board
(?Board?) of the Gavi Alliance (?Gavi?) to convene Participants 1
of the COVAX Facility with the
aim of providing strategic guidance and advice to the Office of the COVAX Facility (?the
Office?) on the operational aspects of the COVAX Facility .
The Council is not deemed to be a committee of the Board in th at its primary role is essentially
an advisory function as contemplated under Article 20 of the Statues. It is empowered by the
Board to undertake the responsibilities outlined in these terms of reference.
2. Membership
Membership of the COVAX Shareholders C ouncil is open to all Participants of the COVAX
Facility.
A representative each from UNICEF, WHO, PAHO, the World Bank, Civil Society and the
AMC92 group of implementing countries shall have a permanent observer seat on the
Shareholders Council.
A. Composition and size
Each Participant may appoint one formal representative to the Council. All members are
treated equally in terms of membership, rights and privileges .
B. Competencies and skills
Council representatives should be empowered to represent thei r government?s policies and
priorities, and reach agreements on their behalf. M embers are expected to be willing and able
to dedicate sufficient time to fulfil Council roles and responsibilities. All members are
expected to act in a manner consistent with the Facility?s goals.
1
Economies who have signed the SFP 2.0 F ramework A greement and fulfilled the necessary financial
requirements or economies who have signed the SFP Transition A greement

Doc 01d - Annex D